3 recruiting, 3 terminated, 2 active not recruiting, 2 completed. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 3, Terminated 3, Active not recruiting 2, Completed 2 |
| Phase 1 | 7 | Active not recruiting 2, Recruiting 2, Terminated 2, Completed 1 |
Follow Recurrent Chronic Myelomonocytic Leukemia: new trials by email Literature Review of Recurrent Chronic Myelomonocytic Leukemia trials Research Report on Recurrent Chronic Myelomonocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Venetoclax - Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2020-09-04 | 2026-06-05 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Canakinumab - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 76 | 2020-08-25 | 2026-05-20 |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Azacitidine, Trametinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2020-07-21 | 2025-04-22 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 97 | 2019-12-17 | 2026-10-06 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
Leukemia, Myelomonocytic, Chronic (10) · Myelodysplastic Syndromes (9) · Leukemia, Myeloid, Acute (6) · Leukemia, Biphenotypic, Acute (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hematologic Neoplasms (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (10) · Chronic Disease (10) · Disease Attributes (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Leukemia (10) · Leukemia, Myeloid (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Myelodysplastic-Myeloproliferative Diseases (9) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3)
Azacitidine (7) · venetoclax (5) · Cytarabine (3) · Decitabine (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Injections (2) · quizartinib (2) · Biopsy (1) · Blood Component Removal (1) · CT-P10 (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dexamethasone (1) · Hematopoietic Stem Cell Transplantation (1)
M.D. Anderson Cancer Center (9) · Fred Hutchinson Cancer Center (1)
United States (10)
Guillermo Garcia-Manero (2) · Guillermo M Bravo (2) · Nicholas Short (2) · Abhishek Maiti, MBBS (1) · Naval G Daver, MD (1) · Naveed Ali, MD (1) · Yesid Alvarado, MD (1)
PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 36841758, PMID 38277619, PMID 38744144, PMID 39537648, PMID 42200455